PVLA
HealthcarePalvella Therapeutics, Inc. · Biotechnology · $1B
What is Palvella Therapeutics, Inc.?
Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on rare and serious genetic skin diseases. Based in Wayne, Pennsylvania, it is working to bring novel therapies to patients with conditions that currently have limited treatment options.
Palvella Therapeutics develops drug candidates targeting mTOR-driven skin diseases — a class of rare genetic conditions affecting the skin and lymphatic system. Its lead candidate, QTORIN rapamycin anhydrous gel, is advancing through clinical trials for microcystic lymphatic malformations and cutaneous venous malformations. The company earns no product revenue at this stage; its value depends entirely on clinical trial outcomes and the eventual path to regulatory approval and commercialization.
Palvella Therapeutics was founded in 2015 and is headquartered in Wayne, Pennsylvania.
- QTORIN rapamycin anhydrous gel — Phase 3 trial for microcystic lymphatic malformations
- QTORIN rapamycin — Phase 2 trial for cutaneous venous malformations
- Broader mTOR-driven skin disease pipeline in early development
Is PVLA a Good Stock to Buy?
UQS Score rates PVLA as Poor overall, reflecting the early-stage nature and elevated risk profile typical of clinical-stage biotechs.
Among the five pillars, Risk comes in at a Neutral rating — the most constructive signal in the profile — suggesting the company's near-term financial structure is not the primary concern relative to peers at a similar development stage.
Quality, Moat, and Growth all register as Weak, which is consistent with a pre-revenue company that has no approved products, no durable competitive advantages yet established, and a pipeline entirely dependent on clinical outcomes. Valuation is rated Elevated, meaning the current market price appears to price in considerable optimism.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PVLA pay dividends?
No — Palvella Therapeutics, Inc. does not currently pay a dividend.
Palvella Therapeutics does not pay a dividend, which is standard for clinical-stage biopharmaceutical companies. All available capital is directed toward funding clinical trials and advancing the pipeline toward regulatory approval. Income-focused investors should look elsewhere; PVLA is a pure capital-appreciation thesis contingent on pipeline success.
When does PVLA report earnings?
Palvella Therapeutics reports financial results on a quarterly cadence, as is standard for US-listed companies.
As a pre-revenue clinical-stage company, quarterly reports focus on cash runway, operating expenses, and clinical trial progress rather than traditional revenue or profit metrics. Pipeline milestones and trial readouts tend to move the stock more than any single earnings release.
For the most recent quarterly results and pipeline updates, visit Palvella Therapeutics' investor relations page directly.
PVLA Price History
+988.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Palvella Therapeutics, Inc.?
Based on Palvella Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
PVLA Long-term Outlook
The fundamental outlook for PVLA is shaped almost entirely by binary clinical trial outcomes. With Growth and Quality both rated Weak, the near-term trajectory depends on whether QTORIN rapamycin can generate positive Phase 3 data for microcystic lymphatic malformations. A successful readout could meaningfully change the company's profile; a setback would likely pressure the stock significantly. The Elevated Valuation rating suggests the market is already pricing in some degree of trial success, which raises the stakes of any negative data.
Growth drivers
- Positive Phase 3 clinical trial readout for microcystic lymphatic malformations
- Expansion of QTORIN rapamycin into additional mTOR-driven skin disease indications
- Potential partnership or licensing deals that could validate the platform
Key risks
- Clinical trial failure — the single largest risk for any pre-revenue biotech
- Elevated Valuation leaves limited margin of safety if trial timelines slip
- Cash burn and potential need for dilutive capital raises before commercialization
PVLA vs Peers
Palvella operates in a broader rare-disease and specialty pharma space alongside companies at varying stages of development.
Amylyx focuses on neurodegenerative diseases rather than skin conditions, representing a different rare-disease therapeutic area with its own distinct regulatory and commercial dynamics.
MindMed develops psychedelic-derived therapies for psychiatric conditions, occupying a very different clinical and regulatory pathway than Palvella's dermatology focus.
Innoviva holds royalty interests in respiratory drugs and has a more mature revenue profile, contrasting sharply with Palvella's pre-revenue clinical stage.
Frequently Asked Questions
What does Palvella Therapeutics do?
Palvella Therapeutics is a clinical-stage biopharmaceutical company developing therapies for rare genetic skin diseases. Its lead program, QTORIN rapamycin anhydrous gel, targets mTOR-driven conditions including microcystic lymphatic malformations and cutaneous venous malformations. The company has no approved products yet and generates no product revenue.
Does PVLA pay dividends?
No, Palvella Therapeutics does not pay a dividend. Clinical-stage biotechs typically reinvest all available capital into research and clinical development. Investors in PVLA are betting on pipeline success rather than income generation.
When does PVLA report earnings?
Palvella Therapeutics follows a standard quarterly reporting cadence for US-listed companies. Because it is pre-revenue, reports center on cash position and trial updates rather than traditional financial performance. Check the company's investor relations page for the latest schedule.
Is PVLA a good stock to buy?
UQS Score rates PVLA as Poor, driven by Weak readings across Quality, Moat, and Growth pillars, alongside an Elevated Valuation. This profile reflects the high-risk, binary nature of clinical-stage biotech investing. Whether it fits your portfolio depends on your risk tolerance and conviction in the pipeline. The full pillar breakdown is available to Pro members.
Is PVLA overvalued?
The UQS Valuation pillar for PVLA is rated Elevated, suggesting the current market price reflects meaningful optimism about clinical outcomes. For a pre-revenue company, valuation is inherently speculative and tied to trial success probabilities rather than traditional earnings-based metrics.
How does PVLA compare to its competitors?
Compared to peers like Amylyx Pharmaceuticals, MindMed, and Innoviva, Palvella is at an earlier commercial stage with no approved products or royalty streams. Its differentiation lies in its dermatology focus and the mTOR mechanism — a relatively targeted scientific approach within rare skin diseases.
What is PVLA's market cap bracket?
Palvella Therapeutics is classified as a small-cap company. This places it in a segment of the market that can experience significant volatility, particularly around clinical trial announcements, and may have limited analyst coverage compared to larger biopharmaceutical peers.
Who founded Palvella Therapeutics?
Palvella Therapeutics was founded in 2015. For detailed information about its founding team and leadership history, the company's official website and SEC filings are the most reliable sources.
Is PVLA a long-term quality investment?
As a long-term quality indicator, PVLA's UQS Score of Poor — with Weak Quality, Moat, and Growth pillars — signals that the company has not yet established the durable characteristics associated with high-quality businesses. Long-term quality typically requires proven revenue, competitive advantages, and financial resilience, none of which Palvella has established yet.
What is the main competitive advantage of Palvella Therapeutics?
Palvella's potential advantage lies in its focus on underserved rare genetic skin diseases and its use of rapamycin — an mTOR inhibitor — delivered via a proprietary anhydrous gel formulation. However, the UQS Moat pillar is rated Weak, reflecting that no durable commercial advantage has been established while the company remains pre-approval.
What sector does PVLA belong to?
Palvella Therapeutics belongs to the Healthcare sector, specifically within clinical-stage biopharmaceuticals. Investors can explore other [healthcare sector stocks](/sector/healthcare) rated by UQS Score to compare quality profiles across the industry.
Unlock Full PVLA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact score for all five UQS pillars
- ✓Access detailed financial metrics behind the rating
- ✓Compare PVLA against sector peers side by side
- ✓Track Quality, Risk, and Valuation changes over time
- ✓Get the complete analyst-style breakdown in one place
Pro Analysis
PVLA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 13.5 | 0.0 | 11.0 | 18.5 | 47.1 | 0.0 | +3.8 |
| May 9, 2026 | 9.7 | 0.0 | 11.0 | 0.0 | 46.2 | 0.0 | -4.9 |
| Apr 22, 2026 | 14.6 | 0.0 | 11.0 | 18.5 | 54.3 | 0.0 | -0.9 |
| Apr 4, 2026 | 15.5 | 0.0 | 11.0 | 23.1 | 54.3 | 0.0 | +1.1 |
| Apr 2, 2026 | 14.4 | 0.0 | 11.0 | 23.1 | 47.1 | 0.0 | — |
PVLA — Pillar Breakdown
Quality
— 0.0/100 (25%)Palvella Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 18.5/100 (20%)Palvella Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 47.1/100 (15%)Palvella Therapeutics, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Palvella Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Palvella Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PVLA.
Score Composition
Financial Data
More Stock Analysis
How is the PVLA UQS Score Calculated?
The UQS (Unified Quality Score) for Palvella Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Palvella Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Palvella Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.